ONTARGET: How much RAS inhibition is enough? Alan B. Weder Clinical Trials Report 19 January 2009 Pages: 7 - 9
Non-pressure-related effects of dietary sodium Guilhem du CailarAlbert Mimran OriginalPaper 19 January 2009 Pages: 12 - 17
The role of incretins in cardiovascular control Derek D. MafongRobert R. Henry OriginalPaper 19 January 2009 Pages: 18 - 22
Stress-induced sodium retention and hypertension: A review and hypothesis Gregory A. HarshfieldYanbin DongCoral D. Hanevold OriginalPaper 19 January 2009 Pages: 29 - 34
A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae Amy I. LynchSteven A. ClaasDonna K. Arnett OriginalPaper 19 January 2009 Pages: 35 - 42
The BEAUTIFUL study: Is heart rate reduction a new therapeutic principle? Frank EnseleitFrank T. Ruschitzka Clinical Trials Report 19 January 2009 Pages: 45 - 47
Vascular insulin resistance: A potential link between cardiovascular and metabolic diseases Ivonne Hernandez SchulmanMing-Sheng Zhou OriginalPaper 19 January 2009 Pages: 48 - 55
Heme oxygenase and renal disease Tambi JarmiAnupam Agarwal OriginalPaper 19 January 2009 Pages: 56 - 62
Angiotensin vaccination: What is the prospect of success? Duncan J. Campbell OriginalPaper 19 January 2009 Pages: 63 - 68
Baroreflex device therapy in the treatment of hypertension Sarada C. UppuluriEugene StorozynskyJohn D. Bisognano OriginalPaper 19 January 2009 Pages: 69 - 75
The hypertension peril: Lessons from CETP inhibitors Matthias HermannFrank T. Ruschitzka OriginalPaper 19 January 2009 Pages: 76 - 80
